369638-68-6

Basic information

• Product Name: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI);N-Boc-2-amino-5-methylpyrazine;2-Boc-Amino-5-methylpyrazine;tert-butyl N-(5-Methylpyrazin-2-yl)carbaMate;CarbaMic acid,N-(5-Methyl-2-pyrazinyl)-, 1,1-diMethylethyl ester;2-N-Boc-aMino-5-Methylpyrazin;1,1-diMethylethyl ester (9CI)
• CAS NO: 369638-68-6
• Molecular Formula: C₁₀H₁₅N₃O₂
• Molecular Weight: 209.245
• EINECS: 200-589-5
• Product Categories: N-BOC
• Mol File: 369638-68-6.mol

Chemical Properties

• Boiling Point: 268.763 °C at 760 mmHg
• Flash Point: 116.344 °C
• Appearance: /
• Density: 1.155 g/cm³
• Vapor Pressure: 0.008mmHg at 25°C
• Refractive Index: 1.543
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 11.63±0.70(Predicted)
• CAS DataBase Reference: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI)(369638-68-6)
• EPA Substance Registry System: Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI)(369638-68-6)

Safety Data

• Hazardous Substances Data: 369638-68-6(Hazardous Substances Data)

Usage

Uses

Since the provided materials do not explicitly mention the uses of Carbamic acid, (5-methylpyrazinyl)-, 1,1-dimethylethyl ester (9CI), it is not possible to list its applications based on the given information. However, given that it is a chemical compound, it may have potential applications in various industries such as pharmaceuticals, agriculture, or materials science, depending on its properties and reactivity. Further research and consultation with experts in the relevant fields would be necessary to determine its specific uses and applications.

InChI:InChI=1/C10H15N3O2/c1-7-5-12-8(6-11-7)13-9(14)15-10(2,3)4/h5-6H,1-4H3,(H,12,13,14)

Upstream product

• 5521-55-1 2-methylpyrazin-5-carboxylic acid 
• 75-65-0 tert-butyl alcohol 
• 4129-17-3 diphenylphosphoranyl azide 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 

Downstream Products

• 369638-69-7 tert-butyl (5-(bromomethyl)pyrazin-2-yl)carbamate 
• 874476-55-8 (5-hydroxymethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester 
• 874476-57-0 5-(tert-butyldiphenylsilanyloxymethyl)pyrazin-2-ylamine 
• 874476-59-2 [5-(tert-butyl-diphenyl-silanyloxymethyl)-pyrazin-2-yl]-thiourea 
• 874476-56-9 [5-(tert-butyl-diphenyl-silanyloxymethyl)-pyrazin-2-yl]-carbamic acid tert-butyl ester 
• 874476-58-1 1-benzoyl-3-[5-(tert-butyl-diphenyl-silanyloxymethyl)-pyrazin-2-yl]-thiourea 
• 369638-71-1 (5-aminomethyl-pyrazin-2-yl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

NITROGEN-CONTAINING FUSED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS

The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.

NITROGEN-CONTAINING FUSED RING COMPOUNDS AS CRTH2 ANTAGONISTS

The present application relates to nitrogen-containing fused ring compounds shown by general formula (I), a pharmaceutically acceptable salt thereof and a stereoisomer thereof as CRTH2 antagonist, wherein X1, X2, X3, X4, X5, W, X, Y, L1, L2, L3, A, B are as defined in the description; the present application further relates to a method for preparing the compounds, a pharmaceutical formulation and a pharmaceutical composition comprising the compounds, a use of the compounds for the manufacture of a medicament for the treatment and/or prevention of diseases related to activity of CRTH2.

Amido Compounds

Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein the variables are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

TYPE II RAF KINASE INHIBITORS

The present invention relates to novel compounds which are able to modulate b-raf kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

CHEMICAL PROCESS 632

A process for preparing pharmaceutically active compounds of formula (I) or a salt thereof wherein R1, n, m, R3, R6, X1, X2, X3 and X4 are as defined in the specification, is described. Novel intermediates are also described and claimed.

FLUORINATED HETEROARYLS

The present invention provides Formula (1A) XN O R 3 HN R 5 O R 4 R 2 R 1 (1A) 5 compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the glucokinase enzyme, where X, R 1, R 2, R 3, R 4, and R 5 are as described herein.

CRYSTALLINE POLYMORPHIC FORM 631

A new polymorphic form of 3-{[5-(azetidin-1-ylcarbonyl)pyrazin-2-yl]oxy}-5-{[(1S)-1-methyl-2-(methyloxy)ethyl]oxy}-N-(5-methylpyrazin-2-yl)benzamide, processes for making it and its use as an activator of glucokinase are described.

SELECTIVE INHIBITORS AGAINST Cdk4 AND Cdk6 HAVING AMINOTHIAZOLE SKELETON

The present invention relates to a compound represented by Formula [I]: wherein X is O, S, NH or CH 2 ; Y 1 , Y 2 , Y 3 , Y 4 and Y 5 , which may be identical or different, are each CH or N; however, at least one of Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is N; Z 1 and Z 2 , which may be identical or different, are each CH or N; n is an integer from 1 to 3; R 1 is a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aliphatic heterocyclic ring or an aromatic heterocyclic ring, or a bicyclic aliphatic saturated hydrocarbon group; R 2 and R 3 , which may be identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkenyl group, a C 3 -C 8 cycloalkyl group, a C 6 -C 10 aryl group, an aromatic heterocyclic ring, or the like; and R 4 is a hydrogen atom, a lower alkyl group, a C 3 -C 6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.

Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9

5-Pyrimidinyl-2-aminothiazole 1 was identified as an inhibitor of cyclin-dependent kinases (CDKs) by a screening of the Merck sample repository. The introduction of a methyl group at the C-5 or C-6 position on the pyrimidine ring, directed toward the gate